Effect of oxandrolone and timing of pubertal induction on final height in Turner's syndrome: randomised, double blind, placebo controlled trial

被引:48
|
作者
Gault, Emma Jane [1 ]
Perry, Rebecca J. [1 ]
Cole, Tim J. [2 ]
Casey, Sarah [3 ]
Paterson, Wendy F. [1 ]
Hindmarsh, Peter C. [4 ]
Betts, Peter [5 ]
Dunger, David B. [6 ]
Donaldson, Malcolm D. C. [1 ]
机构
[1] Univ Glasgow, Royal Hosp Sick Children, Dept Child Hlth, Glasgow G3 8SJ, Lanark, Scotland
[2] UCL Inst Child Hlth, MRC Ctr Epidemiol Child Hlth, London, England
[3] Royal Hosp Sick Children, Dept Clin Trials, Dept Pharm, Glasgow G3 8SJ, Lanark, Scotland
[4] UCL Inst Child Hlth, Clin & Mol Genet Unit, London, England
[5] Southampton Univ Hosp NHS Trust, Dept Paediat, Southampton, Hants, England
[6] Univ Cambridge, Addenbrookes Hosp, Dept Paediat, Cambridge CB2 2QQ, England
来源
关键词
GROWTH-HORMONE TREATMENT; ESTROGEN REPLACEMENT; GIRLS; THERAPY; MULTICENTER; NORMALIZATION; MANAGEMENT; STATURE; AGE;
D O I
10.1136/bmj.d1980
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To examine the effect of oxandrolone and the timing of pubertal induction on final height in girls with Turner's syndrome receiving a standard dose of growth hormone. Design Randomised, double blind, placebo controlled trial. Setting 36 paediatric endocrinology departments in UK hospitals. Participants Girls with Turner's syndrome aged 7-13 years at recruitment, receiving recombinant growth hormone therapy (10 mg/m(2)/week). Interventions Participants were randomised to oxandrolone (0.05 mg/kg/day, maximum 2.5 mg/day) or placebo from 9 years of age. Those with evidence of ovarian failure at 12 years were further randomised to oral ethinylestradiol (year 1, 2 mu g daily; year 2, 4 mu g daily; year 3, 4 months each of 6, 8, and 10 mu g daily) or placebo; participants who received placebo and those recruited after the age of 12.25 years started ethinylestradiol at age 14. Main outcome measure Final height. Results 106 participants were recruited, of whom 14 withdrew and 82/92 reached final height. Both oxandrolone and late pubertal induction increased final height: by 4.6 (95% confidence interval 1.9 to 7.2) cm (P=0.001, n=82) for oxandrolone and 3.8 (0.0 to 7.5) cm (P=0.05, n=48) for late pubertal induction with ethinylestradiol. In the 48 children who were randomised twice, the effects on final height (compared with placebo and early induction of puberty) of oxandrolone alone, late induction alone, and oxandrolone plus late induction were similar, averaging 7.1 (3.4 to 10.8) cm (P<0.001). No cases of virilisation were reported. Conclusion Oxandrolone had a positive effect on final height in girls with Turner's syndrome treated with growth hormone, as did late pubertal induction with ethinylestradiol at age 14 years. However, these effects were not additive, so using both had no advantage. Oxandrolone could, therefore, be offered as an alternative to late pubertal induction for increasing final height in Turner's syndrome.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Effect of oxandrolone and timing of pubertal induction on final height in Turner syndrome: final analysis of the UK randomised placebo-controlled trial
    Gault, Emma Jane
    Cole, Tim J.
    Casey, Sarah
    Hindmarsh, Peter C.
    Betts, Peter
    Dunger, David B.
    Donaldson, Malcolm D. C.
    ARCHIVES OF DISEASE IN CHILDHOOD, 2021, 106 (01) : 74 - 76
  • [2] Final height in Turner syndrome is improved by oxandrolone but not late pubertal induction (14 vs 12 years): results of a UK randomised, double-blind, placebo-controlled study
    Gault, Emma Jane
    Perry, Rebecca J.
    Cole, Tim J.
    Paterson, Wendy F.
    Dunger, David B.
    Hindmarsh, Peter C.
    Betts, Peter
    Donaldson, Malcolm D. C.
    HORMONE RESEARCH, 2009, 72 : 316 - 317
  • [3] The addition of oxandrolone 0.03 mg/kg/day to growth hormone and estrogens improves adult height in Turner syndrome: A randomized, double-blind, placebo-controlled trial
    Menke, Leonie A.
    Sas, Theo C. J.
    de Ridder, Maria A. J.
    Zandwijken, Gladys R. J.
    de Muinck Keizer-Schrama, Sabine M. P. F.
    Otten, Barto J.
    Wit, Jan M.
    HORMONE RESEARCH, 2008, 70 : 177 - 177
  • [4] Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone
    Nilsson, KO
    AlbertssonWikland, K
    Alm, J
    Aronson, S
    Gustafsson, J
    Hagenas, L
    Hager, A
    Ivarsson, SA
    Karlberg, J
    Kristrom, B
    Marcus, C
    Moell, C
    Ritzen, M
    Tuvemo, T
    Wattsgard, C
    Westgren, U
    Westphal, O
    Aman, J
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (02): : 635 - 640
  • [5] Effect of Oxandrolone and Timing of Oral Ethinylestradiol Initiation on Pubertal Progression, Height Velocity and Bone Maturation in the UK Turner Study
    Perry, Rebecca J.
    Gault, Emma Jane
    Paterson, Wendy F.
    Dunger, David B.
    Donaldson, Malcolm D. C.
    HORMONE RESEARCH IN PAEDIATRICS, 2014, 81 (05): : 298 - 308
  • [6] A double-blind, placebo-controlled trial of oxandrolone in inclusion body myositis
    Rutkove, SB
    Parker, RA
    Nardin, RA
    Connolly, CE
    Felice, KJ
    Raynor, EM
    NEUROLOGY, 2001, 56 (08) : A464 - A464
  • [7] Effect of the insulin sensitizer pioglitazone in women with polycystic ovary syndrome: A placebo controlled double blind randomised trial
    Brettenthaler, N
    De Geyter, C
    Huber, P
    Keller, U
    DIABETES, 2003, 52 : A140 - A140
  • [8] Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial
    Mullen, Michael
    Jin, Xu Yu
    Child, Anne
    Stuart, A. Graham
    Dodd, Matthew
    Aragon-Martin, Jose Antonio
    Gaze, David
    Kiotsekoglou, Anatoli
    Yuan, Li
    Hu, Jiangting
    Foley, Claire
    Van Dyck, Laura
    Knight, Rosemary
    Clayton, Tim
    Swan, Lorna
    Thomson, John D. R.
    Erdem, Guliz
    Crossman, David
    Flather, Marcus
    LANCET, 2019, 394 (10216): : 2263 - 2270
  • [9] Randomised double-blind placebo controlled trial comparing oral with vaginal misoprostol for induction of labour
    Yenuberi, H.
    Abraham, A.
    Sebastian, A.
    Benjamin, S.
    Londhe, V
    Mathews, J.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2014, 121 : 94 - 95
  • [10] Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy
    Ubhi, T
    Bhakta, BB
    Ives, HL
    Allgar, V
    Roussounis, SH
    ARCHIVES OF DISEASE IN CHILDHOOD, 2000, 83 (06) : 481 - 487